pfizer glp 1 Pfizer, Novo Nordisk bidding war is just the latest escalation of a lucrative GLP-1 race Pfizer Accelerates Obesity Pipeline with

Notably, 48% of participants planned to take GLP-1RA indefinitely

Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, Ueyama H, Fujisaki T, Saigusa Y, Yamaji T, et al

Cardiovascular risk classification was based on the eligibility criteria used in each cardiovascular outcome trial, rather than a single risk prediction tool such as the Framingham Risk Score

Its effects on inflammatory markers appear similar to other agents in the class, though with potentially less weight loss benefit than newer agents like semaglutide

These differences may reflect expectations as much as outcomes: Younger adults appear more sensitive to side effects, cost, or the friction of staying on treatment, while older adults may weigh benefits differently

Benefits of incretin mimetics By increasing insulin secretion and inhibiting glucagon release, incretin mimetics have blood glucose-lowering effects which help to reduce your HbA1c They have also been shown in clinical research studies to be beneficial in losing weight, compared with a placebo, when used in combination with diet and exercise Side effects Possible side effects of incretin mimetics include: Diarrhoea Nausea Vomiting Headaches Dizziness Increased sweating Indigestion Constipation Loss of appetite GLP1s in the news Due to the approval of semaglutide in the UK in 2023, there has been a surge in popularity of GLP1 drugs and research on the drug class.